Catabasis Pharma (CATB) Tops Q3 EPS by 8c

Catabasis Pharma (NASDAQ: CATB) reported Q3 EPS of ($0.56), $0.08 better than the analyst estimate of ($0.64).

“We have made significant clinical progress with our lead program edasalonexent, a potential foundational therapy for the treatment of Duchenne muscular dystrophy. We are excited that enrollment is complete and target enrollment was exceeded for our Phase 3 PolarisDMD trial of edasalonexent. We very much appreciate the strong interest from physicians and the Duchenne community that propelled trial enrollment. We look forward to reporting top-line results in the fourth quarter of next year,” said Jill C. Milne, Ph.D., Chief Executive Officer of Catabasis. “In preparation for the potential commercialization of edasalonexent, we strengthened our executive team with the addition of Andrew Komjathy as Chief Commercial Officer.”

For earnings history and earnings-related data on Catabasis Pharma (CATB) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
• Cable One names Heather McCallion as chief operating officer